Core Viewpoint - NeurAxis, Inc. is set to report its financial results for the fourth quarter and fiscal year 2025 on March 19, 2026, before market open, with a conference call scheduled for the same day to discuss the results [1]. Company Overview - NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies aimed at addressing chronic and debilitating conditions in both children and adults [4]. - The company is advancing its proprietary technology, IB-Stim®, which is a Percutaneous Electrical Nerve Field Stimulation (PENFS) device, FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and related nausea symptoms in patients aged 8 and older [4]. - NeurAxis is conducting additional clinical trials of PENFS for various pediatric and adult conditions that have significant unmet healthcare needs [4]. Conference Call Details - The conference call will take place on March 19, 2026, at 9:00 am ET, and will be accessible via a live webcast [2]. - Participants can submit questions through the webcast portal or via email [2]. - Call-in participants must register to receive dial-in information and a unique PIN [3]. Additional Information - A replay of the conference call will be available on the company's Investor Relations website [3]. - For further inquiries, investors can contact Lytham Partners [6].
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026